{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:30:00Z","timestamp":1787495400456,"version":"build-2736575974"},"reference-count":41,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,1,11]],"date-time":"2012-01-11T00:00:00Z","timestamp":1326240000000},"content-version":"vor","delay-in-days":2293,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pain"],"published-print":{"date-parts":[[2005,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Buprenorphine is a potent opioid analgesic with partial agonistic properties at \u03bc\u2010opioid receptors. This study investigated the interaction potential with several full \u03bc\u2010agonists in the tail\u2010flick test in mice. We further examined the reversibility of buprenorphine antinociception by different \u03bc\u2010opioid receptor antagonists.<\/jats:p>\n                  <jats:p>Combination of buprenorphine with morphine, oxycodone, hydromorphone and fentanyl in the analgesic dose range resulted in additive or synergistic effects. When given after the decline of the acute buprenorphine effect, both morphine and fentanyl also showed full efficacy. A moderate antagonistic effect according to the partial \u03bc\u2010agonistic properties of buprenorphine was only seen when high doses exceeding the therapeutic dose ranges were combined. Under these conditions antinociception of morphine was reduced to the effect of buprenorphine alone.<\/jats:p>\n                  <jats:p>Prophylactic administration of naloxone (10 mg\/kg i.v.), naltrexone (1 mg\/kg i.v.) and clocinnamox (5 mg\/kg s.c.) fully and persistently blocked the antinociception of a high dose of buprenorphine. An established effect of buprenorphine was less sensitive, although repeated administration of naloxone induced complete antagonism, as did the irreversible antagonist clocinnamox under prophylactic and curative treatment conditions.<\/jats:p>\n                  <jats:p>Our results suggest that the antinociceptive effect of buprenorphine is mainly, if not exclusively, mediated by activation of \u03bc\u2010opioid receptors. They confirm clinical experience that in the analgesic dose range a switch between buprenorphine and full \u03bc\u2010agonists is possible without loss of analgesic efficacy and without a refractory period between the termination of buprenorphine analgesia and the onset of action of the new \u03bc\u2010opioid treatment.<\/jats:p>\n                  <jats:p>Antinociception of buprenorphine is sensitive towards \u03bc\u2010opioid receptor antagonists and incomplete inhibition can be improved by increasing the dose or repetitive dosing.<\/jats:p>","DOI":"10.1016\/j.ejpain.2005.02.002","type":"journal-article","created":{"date-parts":[[2005,3,19]],"date-time":"2005-03-19T18:18:26Z","timestamp":1111256306000},"page":"599-599","source":"Crossref","is-referenced-by-count":71,"title":["Interaction of \u03bc\u2010opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice"],"prefix":"10.1002","volume":"9","author":[{"given":"Babette","family":"K\u00f6gel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Christoph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Stra\u03b2burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmar","family":"Friderichs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,11]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/57.2.192"},{"issue":"2","key":"e_1_2_7_3_1","first-page":"715","article-title":"Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and \u03bc\u2010receptor binding in mice","volume":"271","author":"Burke T.F.","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2004.11.052"},{"key":"e_1_2_7_5_1","first-page":"15P","article-title":"The effects of buprenorphine, morphine and pentazocine on turning behaviour and stereotypy induced by apomorphine in the rat","volume":"27","author":"Cowan A.","year":"1975","journal-title":"J Pharm Pharmacol"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1977.tb07533.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1977.tb07532.x"},{"key":"e_1_2_7_8_1","first-page":"31","volume-title":"Buprenorphine: combatting drug abuse with a unique opioid","author":"Cowan A.","year":"1995"},{"key":"e_1_2_7_9_1","first-page":"74","article-title":"A method for determining loss of pain sensation","volume":"72","author":"D'Amour F.E.","year":"1941","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1981.tb10473.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363190-00003"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(86)80994-5"},{"issue":"1","key":"e_1_2_7_13_1","first-page":"14","article-title":"Naloxone hydrochloride: a review","volume":"58","author":"Goodrich P.M.","year":"1990","journal-title":"AANA J"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(83)80343-6"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-197917020-00001"},{"key":"e_1_2_7_16_1","first-page":"688","article-title":"Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist","volume":"297","author":"Huang P.","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.1.348"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1978.01770280111012"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.40.95"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(95)00078-X"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(97)00170-7"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)02052-6"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704280"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.23-32-10331.2003"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.048835"},{"key":"e_1_2_7_26_1","first-page":"965","article-title":"Sensitivity to the discriminative stimulus and antinociceptive effects of mu opioids: role of strain of rat, stimulus intensity, and intrinsic efficacy at the mu opioid receptor","volume":"289","author":"Morgan D.","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-199902000-00035"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-199809000-00016"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0030-4220(81)90077-3"},{"key":"e_1_2_7_30_1","first-page":"19","article-title":"Buprenorphine TDS: use in daily practice, benefits for patients","volume":"133","author":"Radbruch L.","year":"2003","journal-title":"Int J Clin Pract Suppl"},{"key":"e_1_2_7_31_1","first-page":"65","volume-title":"Characteristics and function of opioids","author":"Rance MJ","year":"1978"},{"key":"e_1_2_7_32_1","first-page":"19","volume-title":"Buprenorphine: combatting drug abuse with a unique opioid","author":"Rothman R.B.","year":"1995"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1258\/002367702320162423"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.51.1.87"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(89)90148-3"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-6576.1999.430909.x"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(81)90529-4"},{"key":"e_1_2_7_38_1","first-page":"1345","article-title":"Buprenorphine antagonism of mu opioids in the rhesus monkey tail\u2010withdrawal procedure","volume":"273","author":"Walker E.A.","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_39_1","first-page":"1523","article-title":"In vivo apparent affinity and efficacy estimates for mu opiates in a rat tail\u2010withdrawal assay","volume":"136","author":"Walker E.A.","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"e_1_2_7_40_1","first-page":"1127","article-title":"Ligand\u2010induced changes in surface mu\u2010opioid receptor number: relationship to G protein activation?","volume":"292","author":"Zaki P.A.","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)01282-1"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(83)90201-4"}],"container-title":["European Journal of Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.ejpain.2005.02.002","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.ejpain.2005.02.002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T12:30:14Z","timestamp":1697113814000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1016\/j.ejpain.2005.02.002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["10.1016\/j.ejpain.2005.02.002"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpain.2005.02.002","archive":["Portico"],"relation":{},"ISSN":["1090-3801","1532-2149"],"issn-type":[{"value":"1090-3801","type":"print"},{"value":"1532-2149","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}